HeartBeam Inc. BEAT Archives - Page 3 of 7

TuesdayAug 08, 2023 1:00 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Appoints Deborah Castillo to Lead Regulatory Strategy and Execution

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for AI. The company today announced its appointment of Deborah Castillo, PhD, as vice president of regulatory affairs. An experienced biomedical engineer with extensive knowledge of FDA, EU and Health Canada regulations, Castillo has significant expertise in cardiovascular diseases, neuroscience and medical devices that support these functions. Prior to joining HeartBeam, Deborah served as director of regulatory affairs neuromodulation at LivaNova, a global medical device company creating…

ThursdayJul 27, 2023 11:58 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q2 2023 Results Call, Webcast

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced that it will hold a conference call to discuss its results for the second quarter ended June 30, 2023. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call at 4:30 p.m. Eastern Time on Thursday, Aug. 10, 2023. Topics will include a review of recent announcements, ongoing initiatives and key 2023 milestones, followed by a question-and-answer period. Interested parties can visit https://ibn.fm/fiRyL to register for…

WednesdayJul 26, 2023 12:50 pm

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Physician, Researcher to Board of Directors

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has announced a new member of its board of directors: Michael R. Jaff, DO. This appointment brings the number of board members to eight. A renowned vascular physician and researcher, Jaff has an impressive background in the clinical and industry space. He will add “a unique and extremely valuable perspective that is crucial for HeartBeam as we progress toward our initial clearances and the commercial availability of our technology,” the announcement stated. Currently the chief…

ThursdayJun 08, 2023 2:08 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Adds Wealth of Expertise to Its Board with Appointments of Ken Nelson and Mark Strome

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced the appointment of Ken Nelson and Mark Strome to its board of directors, effective as of June 5, 2023. Nelson is a 20-year digital health, medical device and remote patient monitoring executive and innovator. Strome brings experience combining over 40 years in the investment management and securities industry. “We are privileged to welcome two members with highly relevant backgrounds to HeartBeam’s board,” said Branislav Vajdic, Ph.D., HeartBeam CEO and founder. “Ken brings extensive experience…

TuesdayMay 30, 2023 12:39 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Enters SAA with Samsung

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced its entry into a strategic alliance agreement (“SAA”) with Samsung, extending the existing SAA between LIVMOR and Samsung. HeartBeam acquired LIVMOR assets earlier this year. Under the agreement, HeartBeam and Samsung will identify and define opportunities for collaboration, tapping the HeartBeam team’s expertise and patented technology in the assessment and monitoring of cardiac symptoms. “The goal of this partnership is to bring standard of care for cardiac diagnostic capabilities to patients by utilizing…

ThursdayMay 25, 2023 2:22 pm

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Granted Key Patent for Use in Innovative System Designed to Help Evaluate Cardiac Symptoms

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, has been granted a patent for the automated cardiac detection technology used in its AIMIGo(TM) System. The company received a notice of allowance from the U.S. Patent and Trademark Office informing the company of the key patent, which relates to the initial AI capability in the form of an expert system for the AIMIGo System. The patent, titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment,” outlines a system that combines the recorded cardiac…

ThursdayMay 18, 2023 1:25 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces FDA 510(k) Submission of HeartBeam AIMIGo(TM) Solution

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (“VECG”) platform intended for patient use at home, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for its HeartBeam AIMIGo(TM) System. The HeartBeam AIMIGo System is a personal, portable and easy-to-use VECG solution to assist patients and their clinicians in assessing cardiac symptoms. The breakthrough solution employs a reusable, credit card-sized, VECG recording device and cloud-based software to deliver critical data in real-time outside of a medical setting. “The 510(k) submission of our HeartBeam AIMIGo…

FridayMay 12, 2023 11:25 am

QualityStocksNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2023 Financial Report, Corporate Updates

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram ("VECG") platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the first quarter 2023, the period ended March 31, 2022. Key takeaways from the report include that the company closed on a $26.5million with a public offering and registered direct offering, raising funds that BEAT anticipates using to execute on upcoming clinical, regulatory and commercial milestones as well as extend cash runway into late 2024. In addition, the report noted that HeartBeam has adjusted its strategic focus to…

WednesdayMay 03, 2023 2:12 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Completes $25M Capital Raise to Achieve Upcoming Milestones, Extend Cash Runway

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions. The company today announced the closing of its secondary offering of 16,666,666 shares of HeartBeam’s common stock. According to the update, the financing will allow HeartBeam to fund its upcoming clinical and regulatory milestones related to its HeartBeam AIMIGo(TM) system and prepare for commercialization in 2024. “We are extremely pleased to have received this additional funding, which will allow us to achieve our important upcoming…

ThursdayMar 30, 2023 2:27 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Offer Timely Solution amid a ‘Smoldering Public Health Crisis’

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere. “A recent study shows that risk factors for cardiovascular (‘CV’) disease are rising among young adults… ‘Yet medical treatment rates for CV risk factors are ‘surprisingly low among young adults,’ study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, told theheart.org/Medscape Cardiology. In the article, Wadhera noted that the findings are ‘extremely concerning.’ He stated that ‘we’re witnessing a smoldering public health crisis. The onset of these risk factors…

Site Search

Company Search

Tag: HeartBeam Inc. BEAT